Clinical Trial Search

Primary: Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores at Rest (NRS-R) Through 48 Hours Postsurgery (AUC0-48). — 386.12; 391.56; 405.82…

Primary: Intracranial Pressure — -0.3; -4.3 cmCSF

Primary: Progression Free Survival (PFS) — 4.8; 7.1 months — p==0.477

Primary: Mean Change From Baseline Freezing of Gait (FOG) After First 12 Weeks of Treatment, as Measured by the Giladi Freezing of Gait Questionnaire (FOG-Q). — 13.75; 14.57…

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) as a Measure of Safety and Tolerability — 11; 12; 9; 12 Participants

Primary: Percentage of Treatment Responders at Month 12; Analyzed in Overall Population — 45.3; 41.1; 50.0; 25.0 percentage of participants — p=0.0292

Primary: Recruitment Feasibility (Time, in Months,) Required to Recruit, Screen and Conduct the Study Procedures — 7.0 months

Primary: Sensitivity (SBR) — 5.49 ratio

Primary: Area Under the Curve (AUC) of Numerical Rating Scale (NRS) Scores (at Rest) Over 72h — 72.30; 66.24; 203.76; 306.58 score on a scale*hour

Primary: The Efficacy of SPN-812 on the Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition (ADHD-RS-IV) — -10.5; -16.7; -18.4; -18.6 units on a scale — p=0.0899

Primary: Total and Delayed Recall on the Hopkins Verbal Learning Test - Revised (HVLT-R) — -0.09679; -0.15776 Z-score — p=0.564

Primary: The Change in Number of Facial Inflammatory Acne-related Lesions. — 46; 23.7 Lesions

Primary: Percentage of Participants With Objective Response (Cohort 1) — 70.1 Percentage of participants — p=<0.0001

Primary: Number of Participants With Acute Toxicity — 23 Participants

Primary: Total Motile Sperm — 8; 1 Participants